X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (384) 384
animals (360) 360
azepines - pharmacology (300) 300
male (293) 293
index medicus (258) 258
azepines - pharmacokinetics (225) 225
pharmacology & pharmacy (216) 216
female (184) 184
rats (155) 155
azepines - administration & dosage (136) 136
adult (133) 133
mice (120) 120
azepines - chemistry (100) 100
pharmacokinetics (99) 99
azepines - therapeutic use (94) 94
middle aged (91) 91
dose-response relationship, drug (76) 76
in vitro techniques (73) 73
administration, oral (72) 72
chemistry, medicinal (71) 71
skin absorption - drug effects (66) 66
azepines - metabolism (64) 64
azepines - adverse effects (62) 62
azepines - blood (61) 61
administration, cutaneous (59) 59
aged (58) 58
half-life (57) 57
kinetics (57) 57
structure-activity relationship (54) 54
azepines - chemical synthesis (52) 52
rats, sprague-dawley (50) 50
time factors (50) 50
biological availability (46) 46
chromatography, high pressure liquid (46) 46
permeability (45) 45
double-blind method (41) 41
in-vitro (41) 41
oncology (41) 41
triazoles - pharmacology (40) 40
cell line, tumor (39) 39
rabbits (39) 39
tissue distribution (39) 39
dogs (37) 37
azone (35) 35
analysis (34) 34
cancer (32) 32
neurosciences (32) 32
skin absorption (32) 32
solubility (31) 31
young adult (31) 31
area under curve (29) 29
skin - metabolism (29) 29
aurora kinase a - antagonists & inhibitors (28) 28
drug interactions (28) 28
pharmacology (28) 28
pharmacology/toxicology (28) 28
treatment outcome (28) 28
biochemistry & molecular biology (27) 27
brain - metabolism (27) 27
protein binding (27) 27
disease models, animal (26) 26
medicine & public health (26) 26
molecular structure (26) 26
pyrimidines - pharmacology (26) 26
discovery (25) 25
injections, intravenous (25) 25
pyrimidines - pharmacokinetics (25) 25
antineoplastic agents - pharmacology (24) 24
drug synergism (24) 24
in-vivo (24) 24
research (24) 24
xenograft model antitumor assays (24) 24
apoptosis (23) 23
brotizolam (23) 23
potent (23) 23
administration, topical (22) 22
chemistry, multidisciplinary (22) 22
chemistry, organic (22) 22
drug design (22) 22
drug therapy (22) 22
toxicology (22) 22
triazoles - pharmacokinetics (22) 22
antineoplastic agents - pharmacokinetics (21) 21
cell biology (21) 21
cross-over studies (21) 21
metabolism (21) 21
models, biological (21) 21
protein kinase inhibitors - pharmacology (21) 21
pyrimidines - administration & dosage (21) 21
rats, inbred strains (21) 21
adolescent (20) 20
antineoplastic agents - administration & dosage (20) 20
apoptosis - drug effects (20) 20
article (20) 20
cell proliferation - drug effects (20) 20
chemistry (20) 20
clinical trials as topic (20) 20
metabolic clearance rate (20) 20
pharmacodynamics (20) 20
safety (20) 20
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 03/2015, Volume 55, Issue 3, pp. 336 - 347
Journal Article
Journal Article
Blood Reviews, ISSN 0268-960X, 2016, Volume 31, Issue 4, pp. 205 - 211
Abstract Approximately 900,000 people are affected by some sort of venous thromboembolic (VTE) event every year in the United States. VTE diagnosis used to... 
Hematology, Oncology and Palliative Medicine | Activated factor X inhibitor | Factor Xa | Anticoagulation therapy | Novel oral anticoagulants | Venous thromboembolism | ED AMERICAN-COLLEGE | RELEVANT DEGREE | WHOLE-BLOOD CLOTS | ATRIAL-FIBRILLATION | CLINICAL-PRACTICE GUIDELINES | ANTITHROMBOTIC THERAPY | HEMATOLOGY | FACTOR XA INHIBITOR | PROCOAGULANT ACTIVITY | DAREXABAN YM150 | Pyrazoles - therapeutic use | Benzamides - pharmacokinetics | Humans | Pyridines - pharmacokinetics | Thiazoles - administration & dosage | Thiazoles - therapeutic use | Rivaroxaban - administration & dosage | Thiazoles - pharmacokinetics | Venous Thromboembolism - drug therapy | Factor Xa Inhibitors - administration & dosage | Pyridones - administration & dosage | Benzamides - administration & dosage | Benzamides - therapeutic use | Benzamides - pharmacology | Factor Xa Inhibitors - pharmacology | Pyrazoles - pharmacokinetics | Rivaroxaban - therapeutic use | Pyrazoles - pharmacology | Pyridines - therapeutic use | Pyridines - administration & dosage | Pyridones - pharmacokinetics | Administration, Oral | Factor Xa Inhibitors - pharmacokinetics | Drug Discovery | Azepines - therapeutic use | Azepines - pharmacology | Factor Xa Inhibitors - therapeutic use | Pyrazoles - administration & dosage | Animals | Blood Coagulation - drug effects | Rivaroxaban - pharmacokinetics | Azepines - pharmacokinetics | Pyridines - pharmacology | Pyridones - therapeutic use | Thiazoles - pharmacology | Rivaroxaban - pharmacology | Azepines - administration & dosage | Pyridones - pharmacology | Anticoagulants (Medicine) | Thromboembolism | Pharmacy
Journal Article
Journal Article
Journal of Pharmacology and Experimental Therapeutics, ISSN 0022-3565, 11/2013, Volume 347, Issue 2, pp. 478 - 486
Journal Article
Investigational New Drugs, ISSN 0167-6997, 8/2015, Volume 33, Issue 4, pp. 942 - 953
Purpose This phase 1 study assessed the pharmacokinetics (PK), maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D), safety, and preliminary efficacy... 
Medicine & Public Health | Alisertib | Oncology | Phase 1 clinical trial | Pharmacology/Toxicology | Pharmacokinetics | Asian | Cancer | MULTIPLE-MYELOMA | SELECTIVE AURORA | ADVANCED SOLID TUMORS | B ACTIVITY | COMBINATION | OVEREXPRESSION | HTLV-1-INFECTED T-CELLS | ONCOLOGY | GROWTH | SQUAMOUS-CELL CARCINOMA | PHARMACOLOGY & PHARMACY | SUPPRESSES | Neoplasms - metabolism | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Aurora Kinase A - antagonists & inhibitors | Young Adult | Antineoplastic Agents - adverse effects | Adult | Female | Antineoplastic Agents - pharmacokinetics | Protein Kinase Inhibitors - pharmacokinetics | Azepines - adverse effects | Pyrimidines - administration & dosage | Treatment Outcome | Azepines - therapeutic use | Neoplasms - drug therapy | Protein Kinase Inhibitors - administration & dosage | Asian Continental Ancestry Group | Maximum Tolerated Dose | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Aged | Azepines - pharmacokinetics | Azepines - administration & dosage | Antimitotic agents | Complications and side effects | Dosage and administration | Research | Antineoplastic agents | Drug therapy | Tumors | Studies | Clinical trials | Inhibitor drugs | Kinases | Cancer therapies | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 04/2016, Volume 34, Issue 12, pp. 1368 - 1375
Purpose Alisertib is an oral Aurora A kinase inhibitor with preclinical activity in neuroblastoma. Irinotecan and temozolomide have activity in patients with... 
SELECTIVE AURORA | SOLID TUMORS | ONCOLOGY | N-MYC | MLN8237 | SCHEDULES | CHILDREN | Dacarbazine - adverse effects | Tablets | Humans | Neuroblastoma - enzymology | Child, Preschool | Drug Resistance, Neoplasm | Male | Neuroblastoma - mortality | Protein Kinase Inhibitors - adverse effects | Aurora Kinase A - antagonists & inhibitors | Young Adult | Time Factors | Camptothecin - administration & dosage | Child | Camptothecin - analogs & derivatives | Protein Kinase Inhibitors - pharmacokinetics | Dacarbazine - administration & dosage | Administration, Oral | Genotype | Disease Progression | Protein Kinase Inhibitors - administration & dosage | Maximum Tolerated Dose | Phenotype | Adolescent | Pyrimidines - pharmacokinetics | United States | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Infant | Aurora Kinase A - metabolism | Glucuronosyltransferase - genetics | Dacarbazine - analogs & derivatives | Adult | Female | Neuroblastoma - pathology | Camptothecin - pharmacokinetics | Camptothecin - adverse effects | Azepines - adverse effects | Drug Administration Schedule | Pyrimidines - administration & dosage | Kaplan-Meier Estimate | Neoplasm Recurrence, Local | Treatment Outcome | Disease-Free Survival | Glucuronosyltransferase - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neuroblastoma - drug therapy | Pyrimidines - adverse effects | Azepines - pharmacokinetics | Azepines - administration & dosage | Index Medicus | Pedi18 | Pedi10 | ORIGINAL REPORTS
Journal Article
Journal Article
Journal Article
Clinical Drug Investigation, ISSN 1173-2563, 7/2018, Volume 38, Issue 7, pp. 631 - 638
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2014, Volume 32, Issue 1, pp. 44 - 50
Purpose Aurora A kinase (AAK) is overexpressed in aggressive lymphomas and can correlate with more histologically aggressive forms of disease. We therefore... 
SURVIVAL | IN-VITRO | ADVANCED SOLID TUMORS | RITUXIMAB PLUS CYCLOPHOSPHAMIDE | ONCOLOGY | SYNTHETIC LETHAL | MYC | VINCRISTINE | MLN8237 | LEUKEMIA CELLS | NF-KAPPA-B | Burkitt Lymphoma - enzymology | Recurrence | Lymphoma, Follicular - drug therapy | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Aurora Kinase A - antagonists & inhibitors | Lymphoma, T-Cell - enzymology | Antineoplastic Agents - adverse effects | Adult | Female | Antineoplastic Agents - pharmacokinetics | Molecular Targeted Therapy - methods | Burkitt Lymphoma - drug therapy | Protein Kinase Inhibitors - pharmacokinetics | Azepines - adverse effects | Lymphoma, Large B-Cell, Diffuse - drug therapy | Drug Administration Schedule | Pyrimidines - administration & dosage | Lymphoma, Large B-Cell, Diffuse - enzymology | Lymphoma, Mantle-Cell - drug therapy | Treatment Outcome | Azepines - therapeutic use | Protein Kinase Inhibitors - administration & dosage | Lymphoma, T-Cell - drug therapy | Lymphoma, Mantle-Cell - enzymology | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Lymphoma, Follicular - enzymology | Aged | Azepines - pharmacokinetics | Azepines - administration & dosage | Hema13 | ORIGINAL REPORTS
Journal Article
Journal Article
Journal Article